Maxime Dely: How Long Can Europe Rely on U.S. Plasma
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”The core issue is clear: American Dependence: How long can Europe rely on U.S. Plasma?
In 2024, nearly 70 % of the world’s plasma used to produce plasma-derived medicinal products came from the United States. A figure that clearly shows how vulnerable Europe remains in a domain essential to patient care.
The U.S. collects around 50 million liters of plasma each year, enabled by a highly industrialized model, a dense network of donation centers, and financial compensation for donors.
By contrast, Europe collects only about 9 million liters, mostly concentrated in Austria, Germany, Hungary, and the Czech Republic. The rest of the continent remains largely dependent on imports.
Since 2023, global demand has been rising quickly (+ 12 to + 14%), driven by increased needs for immunoglobulins. But European collection is growing too slowly to close the gap.
To strengthen supply security, Europe has launched several initiatives:
▪️ EU4Health and resilience programs,
▪️ Investments to modernize collection infrastructures,
▪️ Efforts to increase voluntary non-remunerated donations,
▪️ Expansion of local fractionation capacity.
These initiatives represent real progress, but they come after years of structural dependence. Achieving European plasma sovereignty will require coordinated, long-term, and ambitious action.
The core issue is clear: ensuring continuous and secure access to plasma-derived medicines for all European patients.
In your review, what should be the top priority to rebalance this dependency?
Boosting collection? Rethinking the model? Investing in local production?”
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia